Login

Nilesh Raghunath Khedkar

ORCID: 0000-0003-0607-8071
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5036217672
Research Areas
  • Synthesis and biological activity
  • Quinazolinone synthesis and applications
  • HER2/EGFR in Cancer Research
  • Toxin Mechanisms and Immunotoxins
  • Cancer therapeutics and mechanisms
  • PARP inhibition in cancer therapy
  • Synthesis and Reactions of Organic Compounds
  • Integrated Circuits and Semiconductor Failure Analysis
  • Estrogen and related hormone effects
  • Computational Drug Discovery Methods
  • Click Chemistry and Applications
  • Calcium signaling and nucleotide metabolism
  • Synthesis and Biological Evaluation
  • Ion Channels and Receptors

Manipal Academy of Higher Education
 2024-2025

Lupin Pharmaceuticals (India)
 2020-2025

Cadila Healthcare (India)
 2024

 Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFRWT and EGFRT790M with ADMET Profiling
OPENALEX - Publications 
Nilesh Raghunath Khedkar Milind Sindkhedkar Alex Joseph

10.1016/j.bioorg.2023.107027 article EN Bioorganic Chemistry 2023-12-09
 Computational design, synthesis, and assessment of 3-(4-(4-(1,3,4-oxadiazol-2-yl)-1H-imidazol-2-yl)phenyl)-1,2,4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy
OPENALEX - Publications 
Nilesh Raghunath Khedkar Milind Sindkhedkar Alex Joseph

Herein, we developed innovative EGFR inhibitor using the FBDD approach. Compound 30a emerged as highly potent, selective, capable of arresting cell cycle, and inducing apoptosis, underscoring its potential a novel anticancer therapeutic agent.

10.1039/d4md00055b article EN RSC Medicinal Chemistry 2024-01-01
 Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization
OPENALEX - Publications 
Navnath P. Karche Mandar Bhonde Neelima Sinha Gourhari Jana Gagan Kukreja and 50 more Sanjay P. Kurhade Arun R. Jagdale Ajay R. Tilekar Anil K. Hajare Ganesh R. Jadhav Nishant R. Gupta Rohan A. Limaye Nilesh Raghunath Khedkar Baban Thube Javed S. Shaikh Nageswara Rao Irlapati Samiron Phukan Gopal Gole Apparao Bommakanti Harshal Khanwalkar Y. A. Pawar Ramesh R. Kale Rakesh Kumar Rajesh Gupta Vikas Kumar Saif Wahid Albi Francis Tariq Ahmad Bhat Nivrutti Kamble Vinod Patil Prashant B. Nigade Dipak Modi Shashikant Pawar Sneha Naidu Harish Volam Vamsi Pagdala Sadanand Mallurwar Hemant Goyal Pushpak Bora Prajakta Ahirrao Minakshi Singh Prabhakaran Kamalakannan Kumar Ram Naik Pradipta Kumar Rajendra G. Powar Rajesh B. Shankar Peter R Bernstein Jayasagar Gundu Kumar V.S. Nemmani Lakshmi Narasimham K. S. George Sharad Sharma Dhananjay Bakhle Rajender K. Kamboj Venkata P. Palle

10.1016/j.bmc.2020.115819 article EN Bioorganic & Medicinal Chemistry 2020-10-14
 Design, synthesis, and characterization of 3-(2-(pyrimidin-5-yl)thiazol-4-yl)-1,2,4-oxadiazole derivatives: Anticancer and molecular docking investigations
OPENALEX - Publications 
Nilesh Raghunath Khedkar Alex Joseph Milind Sindkhedkar

Herein, we present a new library of 3-(2-(pyrimidin-5-yl)thiazol-4-yl)-1,2,4-oxadiazole (14a–j) as an anticancer agent designed based on in silico fragment-based drug design (FBDD). The derivatives were synthesized and characterized by 1HNMR,13CNMR, HRMS, FT-IR. was named "pyrimidine-thiazole-1,2,4-oxadiazoles." In addition, the MTT assay used to test compounds for their potential activity panel four human cancer cell lines, such PC3 & DU-145 (prostate cancer), A549 (lung MCF-7 (breast...

10.1080/00397911.2023.2287796 article EN Synthetic Communications 2023-11-26
 Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-N-(2′-methyl-3′-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)benzamide. Structure–Activity Relationship and Preclinical Characterization
OPENALEX - Publications 
Nilesh Raghunath Khedkar Nageswara Rao Irlapatti Disha Dadke Vijay Kanoje Zubair Shaikh and 51 more Vijay Karche Vikas Shinde Gokul Deshmukh Amit B Patil Santosh M. Jachak Samiron Phukan Praveenkumar Anidil Kizhakinagath Milind Gholve Trupti Bhankhede Jagadeesh Daler Harshal Nemade Sagar Budhe Himani Pareek Rajesh Yeshodharan Rajesh Gupta Anil Kalia Dilip K. Pandey Akshaya Wagh Swaroop Kumar Vinod Patil Dipak Modi Nidhi Sharma Prajakta Ahirrao Maneesh Mehta Hemant Kumar Prashant B. Nigade Kaustubh Tamane Sadanand Mallurwar Sandip Kuldharan Shashikant Pawar Gururaj Vishwase Sanjay Bokan Minakshi Singh Kumar Naik Sachin Ingawale Rajesh Shankar P. Kamalakannan Spinvin Venugopal Shaji George Kamlesh J. Padiya Kumar V.S. Nemmani Jaysagar Gundu Mandar Bhonde Lakshmi Narasimham Milind Sindkhedkar Chirag Shah Neelima Sinha Sharad Sharma Dhananjay Bakhle Rajender K. Kamboj Venkata P. Palle

The role of calcium release-activated (CRAC) channels is well characterized and particular importance in T-cell function. CRAC are involved the pathogenesis several autoimmune diseases, making it an attractive therapeutic target for treating inflammatory like rheumatoid arthritis (RA). A systematic structure-activity relationship study with goal optimizing lipophilicity successfully yielded two lead compounds, 36 37. Both compounds showed decent potency selectivity a remarkable...

10.1021/acs.jmedchem.1c01403 article EN Journal of Medicinal Chemistry 2021-11-29
 Modified 9H-fluorene-9-carboxamides as MTP-inhibitors
OPENALEX - Publications 
Saurin Raval Mukul R. Jain Preeti Raval Digvijay Jogiya Krunal Soni and 4 more Jaivinder Yadav Jaymin Barot Nilesh Raghunath Khedkar Amit Joharapurkar

Introduction Metabolic disorder is a cluster of metabolism like hyperglycemia, dyslipidemia and obesity. Any these alone or in combination can lead to high risk for the development levels cholesterol, triglyceride insulin resistance.

10.37285/ijddd.2.4.1 article EN 2024-12-09
Coming Soon ...